Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dengue DNA vaccine - Naval Medical Research Center/Brickell Biotech Inc

Drug Profile

Dengue DNA vaccine - Naval Medical Research Center/Brickell Biotech Inc

Alternative Names: D1ME; Tetravalent dengue plasmid DNA vaccine - Naval Medical Research Center/Brickell Biotech Inc; Tetravalent dengue vaccine - Naval Medical Research Center/Brickell Biotech Inc; TVDV

Latest Information Update: 06 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Naval Medical Research Center; Vical
  • Developer Naval Medical Research Center; United States Army Medical Research and Materiel Command; Vical; Walter Reed Army Institute of Research
  • Class Dengue vaccines; Gene therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Dengue

Most Recent Events

  • 31 Aug 2019 Brickell Biotech has merged with Vical to form Brickell Biotech Inc, and subsequently Brickell Biotech changed its name to Brickell Subsidiary
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Dengue(Prevention) in USA (IM, Injection)
  • 01 Dec 2013 Vical and the US Army Medical Research and Materiel Command complete a phase I trial for Dengue (Prevention) in USA (IM) (NCT01502358)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top